Seoul, South Korea

Heung Mo Kang

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Heung Mo Kang: Innovator in Pharmaceutical Chemistry

Introduction

Heung Mo Kang is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds aimed at treating central nervous system disorders. His innovative work has garnered attention for its potential therapeutic benefits.

Latest Patents

Heung Mo Kang holds a patent for a novel compound, {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate, or a pharmaceutically acceptable salt thereof. This invention includes a production method and a pharmaceutical composition designed to prevent and treat central nervous system disorders. The compound exhibits biological and pharmacological activity comparable to venlafaxine, a known treatment in the field, while demonstrating low toxicity and superior water solubility compared to prior-art venlafaxine derivatives.

Career Highlights

Heung Mo Kang is associated with Je Il Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic options for patients suffering from central nervous system disorders.

Collaborations

Heung Mo Kang has collaborated with colleagues such as Seok Won Kang and Jong Soo Chun, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Heung Mo Kang's contributions to pharmaceutical chemistry highlight his role as an inventor dedicated to enhancing treatment options for central nervous system disorders. His innovative patent reflects a significant advancement in the field, showcasing the potential for improved patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…